【24h】

Reversible mitral and aortic regurgitation due to pioglitazone

机译:吡格列酮引起的可逆性二尖瓣和主动脉反流

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To report the occurrence of pioglitazone-induced reversible valvular regurgitant lesions.Methods: Clinical, laboratory, and imaging data are reported on a patient with known type 2 diabetes mellitus, who was prescribed pioglitazone to achieve better glycemic control.Results: We present a case report of a 50-year-old woman, in whom diabetes had been diagnosed 5 years previously, who developed severe mitral and aortic regurgitation during 5 months of treatment with pioglitazone along with clinical and laboratory indications of fluid retention. Echocardiography 5 months after discontinued use of pioglitazone showed regression of regurgitant lesions and normalization of pertinent laboratory variables.Conclusion: Five months of treatment with pioglitazone could potentially induce major cardiac valvular dysfunction, which was reversible in our patient. This report emphasizes the importance of carefully monitoring patients during treatment with thiazolidinediones.
机译:目的:报告吡格列酮引起的可逆性瓣膜反流病的发生情况。方法:报道了已知患有2型糖尿病的患者的临床,实验室和影像学数据,该患者已处方吡格列酮以实现更好的血糖控制。一名50岁妇女的病例报告,该妇女在5年前被诊断出患有糖尿病,在使用吡格列酮治疗5个月期间出现严重的二尖瓣和主动脉瓣反流以及临床上和实验室上的积水迹象。停用吡格列酮5个月后的超声心动图显示反流性病变消退,相关实验室指标正常化。结论:吡格列酮治疗5个月可能会导致严重的心脏瓣膜功能障碍,在我们的患者中是可逆的。该报告强调了噻唑烷二酮类药物治疗期间仔细监测患者的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号